We hypothesize that neutralizing anti-preS1 antibodies play a role in this shift in HBV particle ratio and may be more present in ID-NAT-nonreactive HBsAg positive donors than in ID-NAT-nonreactive OBI donors, but for the worst-case risk analysis, in the present paper, the infectivity (ID50) in both infection stages was assumed to be the same (316 virions). This evidence concerns the gene BRD2 and infection.